Display options
Cite
Ding G, Li Z, Zhang L, et al. Circulating full-length cytokeratin 18 for predicting prognosis of hepatitis B virus-related acute-on-chronic liver failure patients with lamivudine treatment. Hepatol Res. 2015;46(4):329-34doi: 10.1111/hepr.12549.
Ding, G., Li, Z., Zhang, L., Ma, H., & Li, H. (2016). Circulating full-length cytokeratin 18 for predicting prognosis of hepatitis B virus-related acute-on-chronic liver failure patients with lamivudine treatment. Hepatology research : the official journal of the Japan Society of Hepatology, 46(4), 329-34. https://doi.org/10.1111/hepr.12549
Ding, Guofeng, et al. "Circulating full-length cytokeratin 18 for predicting prognosis of hepatitis B virus-related acute-on-chronic liver failure patients with lamivudine treatment." Hepatology research : the official journal of the Japan Society of Hepatology vol. 46,4 (2016): 329-34. doi: https://doi.org/10.1111/hepr.12549
Ding G, Li Z, Zhang L, Ma H, Li H. Circulating full-length cytokeratin 18 for predicting prognosis of hepatitis B virus-related acute-on-chronic liver failure patients with lamivudine treatment. Hepatol Res. 2016 Apr;46(4):329-34. doi: 10.1111/hepr.12549. Epub 2015 Jul 27. PMID: 26138382.
Copy Download .nbib Format: NLM
Share it on

Hepatol Res. 2016 Apr;46(4):329-34. doi: 10.1111/hepr.12549. Epub 2015 Jul 27.

Circulating full-length cytokeratin 18 for predicting prognosis of hepatitis B virus-related acute-on-chronic liver failure patients with lamivudine treatment.

Hepatology research : the official journal of the Japan Society of Hepatology

Guofeng Ding, Zhi Li, Lei Zhang, Hui Ma, Hui Li

Affiliations

  1. Department of Infectious Disease.
  2. Intensive Care Unit, Binzhou Medical University Hospital, Binzhou, Shandong Province, China.
  3. Departments of Gerontology, Binzhou Medical University Hospital, Binzhou, Shandong Province, China.

PMID: 26138382 DOI: 10.1111/hepr.12549

Abstract

AIM: The predictive value of circulating full-length cytokeratin 18 (M65) on prognosis of hepatitis B virus-related liver failure is still not well investigated. The aim of this study was to reveal the association between serum M65 levels and outcomes of hepatitis B virus-related acute-on-chronic liver failure, and to further clarify clinical significance of M65 in lamivudine treatment.

METHODS: Ninety-six patients with hepatitis B virus-related acute-on-chronic liver failure were recruited between January 2011 and December 2013, and 52 of them received lamivudine treatment. Blood were obtained from participants at admission, and M65 were determined by enzyme-linked immunosorbent assay. Other necessary data were collected from medical records.

RESULTS: The liver failure patients were divided into high and low level groups according to the serum M65 levels. After 24-week follow up, survival incidences were significantly higher in the low level group than that in the high level group (odds ratio [OR] = 0.3, 95% confidence interval = 0.1-0.7). In addition, the survival incidences and albumin levels improved in the patients with lamivudine treatment compared with the patients without lamivudine treatment in the low level group (OR = 5.4, 95% CI = 1.1-26.0 and OR = 4.2, 95% CI = 1.3-13.2). A similar improvement was not observed in the high level group.

CONCLUSION: The study suggested that the circulating M65 may serve as a relatively independent prognostic parameter for liver failure. If prospectively validated in further studies, M65 measurement may also be a useful method for optimizing antiviral therapy.

© 2015 The Japan Society of Hepatology.

Keywords: M65; full-length cytokeratin 18; hepatitis B virus-related liver failure; lamivudine; prognosis

Publication Types